Share on LinkedInShare on LinkedIn

ARTICLE · 03 SEPTEMBER 2024

Federal Circuit's ODP Clarification: A Guide For A Patent Attorney

In the world of patent law, clarity is key. Building on my takeaways from the In re Cellect decision last year, a recent Federal Circuit case, Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 2024-1061, provides essential insights into patent law, offering valuable lessons for any patent attorney.

United StatesIntellectual Property

Authored by Babak Akhlaghi on August 27, 2024. In the world of patent law, clarity is key. Building on my takeaways from the In re Cellect decision last year, a recent Federal Circuit case, Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 2024-1061 (Fed. Cir. August 13, 2024), provides essential insights into patent law, offering valuable lessons for any patent attorney. Here's an overview of the case, key insights, and its implications for patent law.

Executive Summary

Key Clarification: This case clarifies when a patent claim can act as an obviousness-type double patenting (ODP) reference, pivotal for patent lawyers.

Decision Impact: The ruling asserts that a later-filed, later-issued, earlier-expiring patent ('011 Patent) cannot invalidate an earlier-filed, earlier-issued, later-expiring patent ('356 Patent) sharing the same priority. This decision holds significant implications for any patent attorney managing patent portfolios.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from